


Journal of International Oncology››2025,Vol. 52››Issue (9): 560-565.doi:10.3760/cma.j.cn371439-20250414-00095
• Original Article •Previous ArticlesNext Articles
Chen Qiaoliang1, Qin Xinyan2, Lai Ruihe1, Tan Shuangxiu3(
)
Received:2025-04-14Revised:2025-05-21Online:2025-09-08Published:2025-10-21Contact:Tan Shuangxiu E-mail:tsx950304@163.comChen Qiaoliang, Qin Xinyan, Lai Ruihe, Tan Shuangxiu. Diagnostic value of multimodal Nomogram model combining18F-FDG PET/CT and ultrasound for triple negative breast cancer[J]. Journal of International Oncology, 2025, 52(9): 560-565.
"
| 指标 | TNBC(n=12) | 非TNBC(n=49) | t/Z/χ2值 | P值 |
|---|---|---|---|---|
| 年龄(岁) | 55.17±9.19 | 57.35±10.98 | 0.63 | 0.528 |
| SUVmax | 12.88(10.02,24.56) | 7.63(4.92,12.55) | -2.43 | 0.015 |
| SUVmean | 6.10(5.18,8.20) | 4.14(3.45,5.64) | -2.54 | 0.011 |
| SUVmin | 2.53(2.50,2.74) | 2.53(2.51,2.60) | -0.33 | 0.744 |
| MTV(cm3) | 23.68(2.90,71.79) | 6.40(2.82,12.80) | -1.41 | 0.160 |
| TLG(g) | 139.25(13.13,665.44) | 30.81(9.59,74.52) | -1.56 | 0.119 |
| 长径(cm) | 3.55(1.58,5.30) | 2.50(1.80,3.50) | -1.30 | 0.194 |
| 短径(cm) | 2.70(1.18,3.45) | 1.68(1.30,2.10) | -1.78 | 0.075 |
| 病变回声 | ||||
| 低回声 | 10 | 48 | 0.096 | |
| 等、高、 混合回声 |
2 | 1 | ||
| 形态 | ||||
| 规则 | 4 | 1 | 0.004 | |
| 不规则 | 8 | 48 | ||
| 边界 | ||||
| 清晰 | 5 | 5 | 4.86 | 0.028 |
| 不清晰 | 7 | 44 | ||
| 后方回声 | ||||
| 无变化 | 5 | 32 | 0.027 | |
| 衰减 | 3 | 15 | ||
| 增强 | 4 | 2 | ||
| 纵横比 | ||||
| ≥1 | 2 | 9 | <0.01 | >0.999 |
| <1 | 10 | 40 | ||
| 微钙化 | ||||
| 有 | 2 | 17 | 0.74 | 0.389 |
| 无 | 10 | 32 | ||
| 血流分级 | ||||
| 0~1级 | 9 | 20 | 4.52 | 0.034 |
| 2~3级 | 3 | 29 | ||
| BI-RADS分级(分) | ||||
| 4A | 0 | 4 | 0.896 | |
| 4B | 1 | 5 | ||
| 4C | 3 | 9 | ||
| 5 | 8 | 31 | ||
| [1] | Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J].CA Cancer J Clin,2023,73(1): 17-48. DOI:10.3322/caac.21763. |
| [2] | Masci D, Naro C, Puxeddu M, et al. Recent advances in drug discovery for triple-negative breast cancer treatment[J].Molecules,2023,28(22): 7513. DOI:10.3390/molecules28227513. |
| [3] | 谢露露, 丁江华. 免疫治疗在晚期三阴性乳腺癌中的应用进展[J].国际肿瘤学杂志,2023,50(11): 672-676. DOI:10.3760/cma.j.cn371439-20230722-00127. |
| [4] | Adrada BE, Moseley TW, Kapoor MM, et al. Triple-negative breast cancer: histopathologic features, genomics, and treatment[J].Radiographics,2023,43(10): e230034. DOI:10.1148/rg.230034. |
| [5] | Hadebe B, Harry L, Ebrahim T, et al. The role of PET/CT in breast cancer[J].Diagnostics,2023,13(4): 597. DOI:10.3390/diagnostics 13040597. |
| [6] | McDonald ES, Clark AS, Tchou J, et al. Clinical diagnosis and management of breast cancer[J].J Nucl Med,2016,57 Suppl 1: 9S-16S. DOI:10.2967/jnumed.115.157834. |
| [7] | Andryszak N, Świniuch D, Wójcik E, et al. Head-to-head comparison of [18F]PSMA-1007 and [18F]FDG PET/CT in patients with triple-negative breast cancer[J].Cancers (Basel),2024,16(3): 667. DOI:10.3390/cancers16030667. |
| [8] | Romeo V, Kapetas P, Clauser P, et al. A simultaneous multiparametric18F-FDG PET/MRI radiomics model for the diagnosis of triple negative breast cancer[J].Cancers (Basel),2022,14(16): 3944. DOI:10.3390/cancers14163944. |
| [9] | Arslan E, Çermik TF, Trabulus FDC, et al. Role of18F-FDG PET/CT in evaluating molecular subtypes and clinicopathological features of primary breast cancer[J].Nucl Med Commun,2018,39(7): 680-690. DOI:10.1097/MNM.0000000000000856. pmid:29893750 |
| [10] | Seban RD, Arnaud E, Loirat D, et al. [18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab[J].Eur J Nucl Med Mol Imaging,2023,50(13): 4024-4035. DOI:10.1007/s00259-023-06394-y. |
| [11] | Gao Y, Yin L, Ma L, et al. Comparative analysis of metabolic cha-racteristics and prognostic stratification of HER2-low and HER2-zero breast cancer using18F-FDG PET/CT imaging[J].Cancer Imaging,2024,24(1): 166. DOI:10.1186/s40644-024-00812-6. |
| [12] | Roy M, Fowler AM, Ulaner GA, et al. Molecular classification of breast cancer[J].PET Clin,2023,18(4): 441-458. DOI:10.1016/j.cpet.2023.04.002. pmid:37268505 |
| [13] | 康佳, 吴桐, 张蕾, 等. 不同分子分型乳腺癌的多模态超声特征和临床病理对照研究[J].中华超声影像学杂志,2020,29(4): 330-336. DOI:10.3760/cma.j.cn131148-20190926-00591. |
| [14] | Costantini M, Belli P, Bufi E, et al. Association between sonographic appearances of breast cancers and their histopathologic features and biomarkers[J].J Clin Ultrasound,2016,44(1): 26-33. DOI:10.1002/jcu.22312. pmid:26402438 |
| [15] | Sannomiya N, Hattori Y, Ueda N, et al. Correlation between ultrasound findings of tumor margin and clinicopathological findings in patients with invasive ductal carcinoma of the breast[J].Yonago Acta Med,2016,59(2): 163-168. pmid:27493488 |
| [16] | Wang D, Zhu K, Tian J, et al. Clinicopathological and ultrasonic features of triple-negative breast cancers: a comparison with hormone receptor-positive/human epidermal growth factor receptor-2-negative breast cancers[J].Ultrasound Med Biol,2018,44(5): 1124-1132. DOI:10.1016/j.ultrasmedbio.2018.01.013. pmid:29482888 |
| [17] | Ian TWM, Tan EY, Chotai N. Role of mammogram and ultrasound imaging in predicting breast cancer subtypes in screening and symptomatic patients[J].World J Clin Oncol,2021,12(9): 808-822. DOI:10.5306/wjco.v12.i9.808. pmid:34631444 |
| [18] | 刘晓瑜, 林翠君, 黄洁, 等. 不同分子分型乳腺癌的超声、MRI及乳腺X射线摄影特征的诊断价值[J].国际放射医学核医学杂志,2024,48(2): 74-81. DOI:10.3760/cma.j.cn121381-202212013-00349. |
| [19] | Moreel L, Betrains A, Doumen M, et al. Diagnostic yield of combined cranial and large vessel PET/CT, ultrasound and MRI in giant cell arteritis: a systematic review and meta-analysis[J].Autoimmun Rev,2023,22(7): 103355. DOI:10.1016/j.autrev.2023.103355. |
| [20] | 刘春海, 周虎, 刘文静, 等. 超声联合PET/CT及CA153监测乳腺癌术后颈部淋巴结转移的价值[J].中国超声医学杂志,2023,39(3): 261-265. DOI:10.3969/j.issn.1002-0101.2023.03.006. |
| [1] | Radiation Oncology Professional Committee of the Chinese Research Hospital Association, Hebei Society of Mathematical and Physical Medicine, Tianjin Precision Medicine Society.Expert consensus on the clinical diagnosis and treatment of post-obstructive pneumonia in newly diagnosed lung cancer patients[J]. Journal of International Oncology, 2025, 52(8): 484-494. |
| [2] | Li Xiaoxuan, Xia Zhipeng, Luan Rumei, Wan Yunyan, Yao Zhouhong, Lin Xinshan, Lin Dianjie.Clinical value of metabolomics in assessing the malignant risk of pulmonary nodules[J]. Journal of International Oncology, 2025, 52(7): 409-413. |
| [3] | Lai Ruihe, Teng Yue, Rong Jian, Sheng Dandan, Geng Yuzhi, Chen Jianxin, Jiang Chong, Ding Chongyang, Zhou Zhengyang.Predictive value of a combined model for lymph node metastasis in NSCLC based on primary lesion radiomics from18F-FDG PET/CT[J]. Journal of International Oncology, 2025, 52(3): 144-151. |
| [4] | Chen Danlei, Deng Junjun, Li Miao.Progress of clinical application of circulating tumor cells in lung cancer[J]. Journal of International Oncology, 2025, 52(2): 119-123. |
| [5] | Chinese Society of Clinical Oncology-Supportive Care and Rehabilitation Committee, Chinese Expert Consensus Working Group on Cancer-related Anorexia .Chinese expert consensus on the diagnosis and treatment of cancer-related anorexia[J]. Journal of International Oncology, 2025, 52(2): 67-78. |
| [6] | Ji Haitao, Wang Yanfeng, Liu Yongcheng, Hao Nan.Expression and clinical significance of DHCR7 in gastric cancer based on bioinformatics analysis[J]. Journal of International Oncology, 2025, 52(2): 94-100. |
| [7] | Liu Wenhui, Yin Ping, Qi Jie.Diagnostic value of detection of serum G-17,sB7-H3,and DKK1 for early gastric cancer[J]. Journal of International Oncology, 2024, 51(8): 498-503. |
| [8] | Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325. |
| [9] | Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343. |
| [10] | Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291. |
| [11] | Chen Qi, Xu Chenyang, Wang Yin, Lei Dapeng.Current application status of hyperspectral imaging in the diagnosis and treatment of head and neck tumor[J]. Journal of International Oncology, 2024, 51(5): 298-302. |
| [12] | Zhang Lili, Tan Ru, Fang Xueli, Yang Yu, Sang Zheng, Li Baosheng.Imaging diagnosis, pathological upgrade, and imaging technology progress of ductal carcinomain situof the breast[J]. Journal of International Oncology, 2024, 51(3): 166-169. |
| [13] | Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185. |
| [14] | Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104. |
| [15] | Sun Haomiao, Sun Haibo, Sun Jianling.Application value of serum MAGEA3 and HE4 in the auxiliary diagnosis of lung cancer patients[J]. Journal of International Oncology, 2024, 51(12): 749-754. |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||